{"id":"NCT00698932","sponsor":"AstraZeneca","briefTitle":"Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control","officialTitle":"A 24-Week International, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06","primaryCompletion":"2009-10","completion":"2009-10","firstPosted":"2008-06-17","resultsPosted":"2011-09-21","lastUpdate":"2011-09-21"},"enrollment":568,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Saxagliptin","otherNames":["Onglyza"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Saxagliptin 5mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients with inadequate glycaemic control with diet and exercise.","primaryOutcome":{"measure":"Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c)","timeFrame":"Baseline , Week 24","effectByArm":[{"arm":"Saxagliptin 5 mg","deltaMin":8.15,"sd":0.05},{"arm":"Placebo","deltaMin":8.14,"sd":0.05}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":30,"countries":["China","India","Philippines","South Korea"]},"refs":{"pmids":["27402391"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":284},"commonTop":["Upper Respiratory Tract Infection"]}}